Results 1 to 10 of about 10,921 (199)

The effect of optic neuritis treatment trial (ONTT) combined corticosteroid regimen on pattern reversal visual evoked potentials: a prospective follow-up study [PDF]

BMC Ophthalmology, 2021
Background The combined corticosteroid regimen of the original Optic Neuritis Treatment Trial (ONTT) is used in many centers to treat optic neuritis. Though pattern reversal visual evoked potentials (PRVEPs) are a sensitive, standard measure of visual ...
Padmini Dahanayake, Tharaka L. Dassanayake, Manoji Pathirage, Saman Senanayake, Mike Sedgwick, Vajira S. Weerasinghe   +5 more
doaj   +2 more sources

Development of a predictive model for predicting disability after optic neuritis: a secondary analysis of the Optic Neuritis Treatment Trial

Frontiers in Neurology
ObjectiveThe present study aimed to develop a prediction model for predicting developing debilities after optic neuritis.MethodsThe data for this research was obtained from the Optic Neuritis Treatment Trial (ONTT).
Siqian Wei, Yi Du, Meifeng Luo, Ruitong Song   +3 more
doaj   +5 more sources

Patients' knowledge and perception on optic neuritis management before and after an information session [PDF]

BMC Ophthalmology, 2010
Background Patients' understanding of their condition affect the choice of treatment. The aim of this study is to evaluate patients' understanding and treatment preferences before and after an information session on the treatment of acute optic neuritis.
Klaer Pamela, McCarl Helen, Keane Miriam C, Matti Albert I, Chen Celia S   +4 more
doaj   +3 more sources

From the Optic Neuritis Treatment Trial to Antibody-Mediated Optic Neuritis: Four Decades of Progress and Unanswered Questions [PDF]

Biomedicines
Optic neuritis (ON) has been recognized since antiquity, but its modern clinical identity emerged only in the late 19th century and was definitively shaped by the Optic Neuritis Treatment Trial (ONTT).
Marco A. Lana-Peixoto, Natália C. Talim, Paulo P. Christo   +2 more
doaj   +2 more sources

Neuroprotection in a novel mouse model of multiple sclerosis. [PDF]

PLoS ONE, 2013
Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process of drug development.
Katie Lidster, Samuel J Jackson, Zubair Ahmed, Peter Munro, Pete Coffey, Gavin Giovannoni, Mark D Baker, David Baker   +7 more
doaj   +5 more sources

Parent and medical professional willingness to enroll children in a hypothetical pediatric optic neuritis treatment trial

Frontiers in Neurology, 2011
The Optic Neuritis Treatment Trial and subsequent studies have had a tremendous impact on the treatment and prognosis of optic neuritis and multiple sclerosis in adults. The results of these studies have been extrapolated to children; however, pediatric
Amy eWaldman, Michael eShumski, Grant T. Liu   +2 more
doaj   +3 more sources

A Challenging Case of MOG-Associated Optic Neuritis: The Role of IL-6 Inhibition in Refractory Disease [PDF]

International Medical Case Reports Journal
Hind Alnajashi,1,2 Mesedah Alnahdi2 1Neurology Department, King Abdulaziz University, Jeddah, Saudi Arabia; 2Neurology Department, King Abdulaziz University Hospital, Jeddah, Saudi ArabiaCorrespondence: Hind Alnajashi, Neurology Department, King ...
Alnajashi H, Alnahdi M
doaj   +2 more sources

Trial for a trial: Is there hope? – Optic neuritis treatment trial protocol in patients with traumatic optic neuropathy

Kerala Journal of Ophthalmology, 2020
Aims: The aim of this study was to analyze the clinical profile, visual outcome, factors predicting the visual outcome, and response to systemic methylprednisolone as per the Optic Neuritis Treatment Trial (ONTT) protocol in patients with traumatic optic
Jainy Joseph Emmatty, Smita Narayan, Rajini K Cherayath   +2 more
doaj   +2 more sources

The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy [PDF]

Trials
Background In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination.
Gioia Riboni-Verri, Christopher E. McMurran, Trisha Mukherjee, Cyrus Daruwalla, Jonathon Holland, Riddhima Gautam, Benson S. Chen, Emma Cutting, Wendi Qian, David MacManus, Declan T. Chard, J. William L. Brown, Alasdair J. Coles, Nick G. Cunniffe   +13 more
doaj   +2 more sources

Successful Management of Isolated Optic Neuritis in Acute Diseminated Encephalomyelitis: A Case Report [PDF]

Annals of Mechnikov's Institute, 2021
Background: Optic neuritis is an inflammatory disease that results in demyelination of the optic nerve. Isolated Optic Neuritis in Acute Disseminated Encephalomyelitis is a rare case, this disease attacks the central nervous system. It is monophasic, and
Arantrinita Arantrinita, Agustini Lukisiari   +1 more
doaj   +2 more sources